Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2023-10-04 Board/Management Inform…
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Board Meeting — Dividend
Board/Management Information Classification · 95% confidence The document is a short notice dated October 4, 2023, informing the stock exchanges about an upcoming Board Meeting scheduled for October 9, 2023. The purpose of the meeting includes consideration and declaration of an interim dividend for the financial year 2023-24. It also mentions the record date for the dividend and the closure of the trading window as per insider trading regulations. The document is a formal announcement related to board activities and compliance with regulatory disclosure requirements. It does not contain any financial statements, detailed financial data, or full report content. The length is only 2319 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces a board meeting and related corporate actions.
2023-10-04 English
Credit Rating
Audit Report / Information Classification · 95% confidence The document is a detailed rating rationale issued by India Ratings and Research regarding Glenmark Life Sciences Limited's bank facilities. It discusses the current ratings, rating watch status, ownership changes, financial summary, rating history, and other credit-related information. The content is focused on credit ratings and financial health rather than a full annual or quarterly financial report. It is not a certification, announcement of a report, or a brief summary. The document is a standalone audit/credit rating report providing detailed analysis and rating actions, which fits the category of Audit Report / Information (AR). FY 2023
2023-10-04 English
Public Announcement-Open Offer
Regulatory Filings
2023-09-28 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed communication addressed to stock exchanges regarding the 12th Annual General Meeting (AGM) of Glenmark Life Sciences Limited held on September 26, 2023. It includes a summary of the AGM proceedings, the Scrutinizer's Report on voting, and voting results. The content covers the conduct of the AGM, resolutions passed, voting procedures, and compliance with regulatory requirements. There is no indication that this is the full annual report or financial statements, but rather a report on the AGM event and voting outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which includes official results from shareholder votes at any general meeting. The document length and detail confirm it is not a brief announcement or a simple report publication notice. Therefore, the appropriate classification is DVA.
2023-09-26 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a formal communication from Glenmark Life Sciences Limited to stock exchanges regarding the withdrawal of a voluntary issuer rating disclosure by India Ratings due to regulatory requirements. It includes a detailed explanation of the rating withdrawal, references to SEBI regulations, and clarifies that outstanding instrument ratings remain unaffected. The document is an announcement informing stakeholders about a regulatory compliance action and does not contain financial statements, management discussion, or detailed financial data. It is not a full report but an official notification of a regulatory event related to credit rating disclosures. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-09-23 English
Open Offer
M&A Activity Classification · 95% confidence The document is a Public Announcement dated September 21, 2023, regarding an open offer for acquisition of shares of Glenmark Life Sciences Limited by Nirma Limited. It references compliance with the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeover) Regulations, 2011, and details the offer size, price, mode of payment, and the underlying transaction triggering the open offer obligations. The document is an official announcement to stock exchanges and public shareholders about the open offer and related regulatory compliance. It does not contain financial statements or detailed financial performance data but is a formal disclosure of a takeover bid. Therefore, it fits the category of M&A Activity (TAR) filings, which cover announcements and documents related to merger proposals or takeover bids.
2023-09-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.